Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: 

• Bellerophon Therapeutics (BLPH), 637% surge in interest
• Sage Therapeutics (SAGE), 340% surge in interest
• Armata Pharmaceuticals (ARMP), 317% surge in interest
• Akebia Therapeutics (AKBA), 261% surge in interest
• Coherus Bio (CHRS), 179% surge in interest

Pipeline and key clinical candidates for these companies:

Bellerophon Therapeutics is focused on developing therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is currently developing multiple product candidates under its INOpulse program, a proprietary pulsatile nitric oxide delivery system.

Sage Therapeutics is a biopharmaceutical company “fearlessly leading the way to create a world with better brain health.” The company’s mission is to “pioneer solutions to deliver life-changing brain health medicines, so every person can thrive,” Sage has stated.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is “committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage-specific GMP manufacturing,” the company states.

Akebia Therapeutics is a fully integrated biopharmaceutical company that says its purpose is “to better the lives of people impacted by kidney disease.”

Coherus is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer and the commercialization of our portfolio of FDA-approved therapeutics. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated through net sales of its diversified portfolio of FDA-approved therapeutics.

Recent news on these stocks:

July 27

Scotiabank initiated coverage of Sage Therapeutics with an Outperform rating and $61 price target. The analyst believes the company’s approach toward drug development related to neurosteroid biology could bring novel classes of compounds to disease markets in need of innovative alternatives. In addition, pipeline success could make Sage an attractive acquisition target, the analyst told investors in a research note.

July 24

Citi initiated coverage of Coherus Biosciences with a Buy rating and $12 price target. Coherus is an “underappreciated biotech company with a unique dual business model,” including a rapidly expanding commercial biosimilar franchise and an innovative immuno-oncology pipeline, the analyst told investors in a research note. The firm thinks Coherus is entering a “significant period of re-growth,” driven by new biosimilar launches, the pending toripalimab approval, and clinical advancement of its existing I/O assets.

July 18

Akebia Therapeutics completed an End of Dispute Type A meeting with the FDA to discuss Akebia’s forthcoming resubmission of its New Drug Application, or NDA, for vadadustat as a treatment for anemia due to chronic kidney disease in adult patients on dialysis. Akebia expects to receive the FDA’s meeting minutes by mid-August and plans to resubmit its NDA for vadadustat by the end of the third quarter of 2023. Upon acceptance of the NDA, Akebia expects the FDA to set a PDUFA date of six months from the date of submission.

Hear more from InvestingChannel by signing up for The Spill.

About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 20-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.